Life science news and medical media coverage for healthcare professionals
Endocrinology19 Sept 2026
Sex and hypoglycaemia in type 1 diabetes: what CGM data now showRead article
Why are we still treating cancer prevention as adjunctive care?
Adopting a healthy lifestyle correlates with reduced risk for 13 distinct cancer types, highlighting the role of modifiable factors in oncology.
Breast cancer home injections: Convenient for patients, complex for insurers
Despite the clinical benefits of home-based breast cancer therapy, insurance policies frequently impede patient access to these convenient injection programs.
Salivary gland cancer: Is HER2-low the new HER2-positive?
Trastuzumab rezetecan demonstrated antitumor activity in advanced salivary gland carcinoma, particularly in HER2-high disease, with a 50% objective response rate.
Lung cancer in never smokers: The 60x risk factor you might be missing
Olaparib: Why HRD in breast and ovarian cancer goes beyond BRCA
Multicancer tests: Can we screen without knowing the outcome?
Multicancer early detection: Can we screen for what we can't treat?
Brain metastases: Why less radiation, more often, improves outcomes
Chemo hair loss: Why some patients feel it more deeply
Liver disease: Is coffee a daily dose of prevention?
Regular coffee consumption is associated with a reduced risk of liver disease, with a specific daily intake range appearing most beneficial. The protective effect extends across various liver conditions, including fibrosis and cirrhosis.
MASH: Why diabetes management now demands a liver-first approach?
Emerging liver-directed approaches for moderate to advanced MASH are reshaping treatment paradigms, with significant implications for diabetes specialists managing metabolic dysfunction.
Chronic hepatitis B: Is PD-1 blockade the key to T-cell revival?
A 24-week anti-PD-1 antibody regimen reduced HBsAg and enhanced HBV-specific T cell responses in patients with chronic hepatitis B, offering a potential functional cure strategy.
Seladelpar and Elafibranor: The Second-Line Options for PBC After Ursodeoxycholic Acid Fails
Pruritus in primary biliary cholangitis: the symptom that drives quality of life
ACLF: Why G-CSF works for some, but fails others
Why primary sclerosing cholangitis remains a therapeutic graveyard
Seladelpar and elafibranor: second-line options for PBC
Cholangiocarcinoma Surveillance: What Interval, What Modality in PSC?
Peripheral arterial disease: Why early detection still eludes us
Peripheral arterial disease often goes undiagnosed until advanced stages, leading to preventable complications. Early detection is critical for improving patient outcomes.
LAA occlusion: Less bleeding, but is stroke risk truly equal?
Left atrial appendage occlusion (LAAO) reduces nonprocedural bleeding in AF patients but shows no difference in stroke or mortality compared to medical therapy.
Beyond diagnosis: ECG waveforms predict MI-E treatment response
Electrocardiogram waveforms offer insights into myocardial infarction with epicardial coronary artery disease (MI-E) efficacy, providing a non-invasive window into myocardial health.
Tactical athletes need more than a sports physical
GLP-1s: Is eligibility missing half your high-risk patients?
Evolocumab: Is LDL-C reduction finally translating to lives saved?
Hypertension: Do shorter wall squats work as well for older women?
Endocarditis: Why fixed-dose ampicillin often misses the mark
Rethinking xylitol: Is this 'healthy' sugar substitute a cardiac threat?
Bariatric surgery: The hidden hernia risk you're missing
Up to 20% of bariatric surgery candidates present with pre-existing ventral hernias, a significant comorbidity often overlooked in surgical planning.
CBL-514: Is visceral fat reduction the real story?
CBL-514 reduced visceral fat volume by 10.45% versus a 11.76% rise on placebo in a 40-person MRI subgroup, but the weight regain claim rests on rat data.
Marathon running with type 1 diabetes: Is it finally safe?
Adults with type 1 diabetes can safely complete marathons by leveraging continuous glucose monitoring (CGM) and traditional glucometers for real-time glucose management.
Amylin plus tirzepatide: Is 23% weight loss the new benchmark?
The 2026 ADA/EASD consensus: Why early SGLT2/GLP-1 works
Rotavirus vaccine and T1D: Is an 11% rise cause for alarm?
Survodutide: Is 9.8% weight loss enough for its GI cost?
Type 1 diabetes screening: Why one protocol worked across 8 nations
Low-carb diets in kids with type 1 diabetes: safe, but not standard?
Tau: Why its 'knockout' effect is a clue to Alzheimer's
Tau hyperphosphorylation impairs cooperative binding to microtubules and disrupts lysosome trafficking in neurons, mimicking tau knockout effects.
Brexpiprazole for Alzheimer's agitation: Antidepressants don't change efficacy
A post hoc analysis found brexpiprazole reduced agitation in Alzheimer's dementia, with similar efficacy regardless of concomitant antidepressant use.
Can mice learn to control their own brains? A new neurofeedback system
A real-time closed-loop neurofeedback system allowed mice to modulate cortical activity and movement, adapting to rule changes for reward acquisition.
Epilepsy: Is art the missing piece in holistic patient care?
Parkinson's cognitive decline: Is Juvmo the answer we overlooked?
Lifelong odor sensitivity: What early exposure means for your patients?
Spike sorting: Is your 'black box' holding back neural insights?
Fibromyalgia: Is the pain real if the tissue damage isn't?
Routine childhood vaccines: Less coverage means more than just infections
R-CHOP has been standard of care for 20 years. frontMIND may be the beginning of the end
An epidemiological shift in T2D is reshaping drug development and market access for oncology and metabolic portfolios.
The most resistant cancer is finally responding, and the pipeline is accelerating
Lecanemab and donanemab are approved. The harder question is who gets them and how
Label expansion triples the eligible population and the infrastructure race begins
LeukemiaRusfertide and hepcidin mimetics: a different way to control erythrocytosis
Get the full storyHaematocrit targets: Is 45% still the right threshold for phlebotomy?
Get the full storyWhy molecular response in polycythemia vera remains an elusive endpoint
Get the full storyPNH: Beyond Eculizumab, How Proximal Inhibition Reshaped Treatment Goals
Get the full storyWhen complement inhibitors fail: Recognizing breakthrough haemolysis
Get the full storyOral factor B inhibition: a new path for PNH management?
Get the full storyMyelofibrosis: Why transplant timing dictates survival, not just symptoms
Get the full storyChoosing a JAK Inhibitor in Myelofibrosis: Beyond Ruxolitinib
Get the full storyMomelotinib and anaemia in myelofibrosis: a new calculus for treatment?
Get the full storyGene therapy for thalassemia: Approval is one hurdle, access is the next
Get the full story
Idiopathic Pulmonary Fibrosis
Clostridioides difficile
AdvertisementAdvertisementAdvertisement
• Oct 21 – 23ESMO 2026 • Madrid, ES 
• Oct 23 – 27ACR 2026 • Orlando, US 
• Nov 6 – 11AHA 2026 • Chicago, US • Nov 6 – 9ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12LIVEJoint ACTRIMS-ECTRIMS 2026 • Toronto, CA • Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27ACR 2026 • Orlando, US • Nov 6 – 11AHA 2026 • Chicago, US • Nov 6 – 9ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12
Advertisement
TorontoOct 21 – 23 2026Get on-site reporting the moment it publishes.
TorontoAttending Joint ACTRIMS-ECTRIMS 2026?
Get our free prep guide: key sessions by day, satellite symposia listings, and recommended spots near the venue.
Free. No spam. Unsubscribe anytime.
